Drug Trial Radar · NCT07795593
Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
May 2031
Study completion Jul 2031
Sponsor
- Lead sponsor
- University of MichiganAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The research team will perform a comparative-effectiveness sequential, multiple assignment, randomized trial in painful diabetic neuropathy (PDN) patients for 8 total months, divided into two 4-month stages. 600 participants 18+ with PDN will be enrolled in this study. The main goal is to compare the utility of three modalities (oral, topical, and behavioral) for initial PDN treatment, and to compare the utility of switching modalities versus continuing with the same modality for non-responders. Pain and discontinuation will be assessed weekly, whereas other outcomes will be assessed monthly for 8 months.
Conditions
- Painful Diabetic Neuropathy (PDN)
- Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT)Device
Participants will work with study team to begin web-based, self-guided CBT (non-significant risk device) or traditional (one on one) CBT with a therapist (behavioral, not a device).
Oral MedicationDrug
Participants will work with their physician to select an oral medication from a list commonly used to treat PDN. Patients will follow standard of care dosing and tapering of the assigned drug. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's): Duloxetine, Venlafaxine, Desvenlafaxine Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline Gabapentinoids: Gabapentin, Pregabalin Sodium Channel Blockers: Oxcarbazepine, Lamotrigine, Lacosamide
Topical MedicationDrug
Participants will work with their physician to select a topical medication from a list commonly used to treat PDN. 0.075% capsaicin cream (4 times daily) 4-5% lidocaine patches (1-4 patches every 24 hours)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-centered utility function as a measure for efficacy and tolerabilityTime frame: Up to 8 months.
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California
University of Florida-Jacksonville
Jacksonville, Florida
Rush University Medical Center
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Tulane University
New Orleans, Louisiana
Johns Hopskins University
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Allina Health-Neurosciences Research
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
University of Missouri
Columbia, Missouri
University of Nebraska
Omaha, Nebraska
Columbia University
New York, New York
Weill Cornell Medicine
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Duke University
Durham, North Carolina
Oregon Health & Science University
Portland, Oregon
University of Pittsburgh
Titusville, Pennsylvania
Meharry Medical College
Nashville, Tennessee
University of Vanderbilt
Nashville, Tennessee
DHR Health Institute for Research and Development
Edinburg, Texas
BaylorScott & White University Medical Center
McKinney, Texas
Essentia Health
Spooner, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.